- Home
- DNUT vs NVCR Comparison
DNUT vs NVCR Comparison
Compare DNUT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- NVCR
- Stock Information
- Founded
- DNUT 1937
- NVCR 2000
- Country
- DNUT United States
- NVCR Switzerland
- Employees
- DNUT N/A
- NVCR N/A
- Industry
- DNUT Food Chains
- NVCR Medical/Dental Instruments
- Sector
- DNUT Consumer Staples
- NVCR Health Care
- Exchange
- DNUT Nasdaq
- NVCR Nasdaq
- Market Cap
- DNUT 505.6M
- NVCR 1.9B
- IPO Year
- DNUT 2021
- NVCR 2015
- Fundamental
- Price
- DNUT $3.35
- NVCR $17.71
- Analyst Decision
- DNUT Buy
- NVCR Buy
- Analyst Count
- DNUT 8
- NVCR 6
- Target Price
- DNUT $10.23
- NVCR $32.83
- AVG Volume (30 Days)
- DNUT 3.9M
- NVCR 1.6M
- Earning Date
- DNUT 08-07-2025
- NVCR 07-24-2025
- Dividend Yield
- DNUT 4.22%
- NVCR N/A
- EPS Growth
- DNUT N/A
- NVCR N/A
- EPS
- DNUT N/A
- NVCR N/A
- Revenue
- DNUT $1,597,883,000.00
- NVCR $621,711,000.00
- Revenue This Year
- DNUT N/A
- NVCR $5.56
- Revenue Next Year
- DNUT $2.80
- NVCR $9.19
- P/E Ratio
- DNUT N/A
- NVCR N/A
- Revenue Growth
- DNUT N/A
- NVCR 18.27
- 52 Week Low
- DNUT $2.50
- NVCR $14.17
- 52 Week High
- DNUT $12.68
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- DNUT 61.12
- NVCR 51.32
- Support Level
- DNUT $2.50
- NVCR $17.53
- Resistance Level
- DNUT $2.72
- NVCR $18.70
- Average True Range (ATR)
- DNUT 0.18
- NVCR 0.72
- MACD
- DNUT 0.12
- NVCR 0.09
- Stochastic Oscillator
- DNUT 83.67
- NVCR 60.56
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.